Co-Inventors
Purcell, Robert (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Moayeri, Mahtab (NIAID)
Leppla, Stephen (NIAID)
Therapeutic Areas
Infectious Disease
Immunology
The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent toxin-neutralizing activity, while the anti-capsule mAb efficiently kills anthrax bacteria. By merging these specificities into a single lgG framework, the resulting bispecific antibody can simultaneously neutralize toxins and kill bacteria, potentially offering comprehensive protection against anthrax infection. The bispecific antibody is produced from transfected mammalian cells, ensuring scalability for large-scale production. This technology represents a significant advancement in anthrax biodefense, providing a simpler, more effective approach for treatment following exposure to aerosolized B. anthracis spores.
Commercial Applications
The tetravalent bispecific antibody targeting anthrax toxins and capsule has significant potential applications in biodefense and anthrax treatment. It could be used as a post-exposure prophylactic following potential exposure to aerosolized B. anthracis spores, offering rapid and targeted protection. Additionally, this antibody may find utility in the treatment of anthrax infections, potentially improving outcomes and reducing the need for complex treatment regimens. Its ability to target multiple virulence factors simultaneously makes it a promising candidate for use in biodefense strategies against anthrax.
Competitive Advantages
The tetravalent bispecific antibody targeting anthrax toxins and capsule offers several competitive advantages over existing approaches. Unlike conventional monoclonal antibodies that target only one antigen, this bispecific antibody can simultaneously neutralize toxins and kill bacteria, providing comprehensive protection against anthrax infection. Additionally, the simplicity of using a single molecule instead of a combination of two monoclonal antibodies enhances efficacy and ease of administration. The ability to express and purify the antibody from transfected mammalian cells ensures scalability for large-scale production, further enhancing its potential as a biodefense tool.
